A non-functional small intestine can result in malabsorption and this disorder is referred to as short bowel syndrome (SBS). The principal symptom is diarrhea, which can lead to dehydration, malnutrition, and weight loss. This disorder can either be inherited or acquired; the latter condition is primarily observed in patients with nearly half the small intestine removed due to an underlying disease condition. Favorable reimbursements offered by governments account for one of the key driving factors of the market, especially in regions such as North America.
As per the report by Transparency Market Research, the global short bowel syndrome market is expected to grow at a CAGR of 30.4% to reach a valuation of US$2.6 bn by the end of 2024, as compared to US$312.7 mn in 2016. The percentage of diagnosis has been comparatively low for short bowel syndrome due to the rarity of this disease. In addition, approved drugs for SBS are not easily available across the globe, which has resulted in a significant pool of unmet clinical needs.
Get Sample Research Report:
What makes North America the undisputed leader in the global SBS market?
The exclusivity of Gattex – a GLP-2 drug in the U.S. is projected to contribute to the rising revenue of the global as well as U.S. market. Among North America, Europe, and Rest of the World, the North American region is expected to dominate the market in the coming years as well. The main factor driving this market is the increasing prescription of Gattex therapy in the said region. Plus, considering the fact that growth hormones and glutamine are only permitted in the U.S. for treating SBS, North America will continue to be in the lead. Favorable reimbursement strategies and rising responsiveness about short bowel syndrome amongst consumers are fuelling the market in this region.
The uncommonness of the disease and the need to spread awareness has resulted in healthcare organizations such as the National Organization for Rare Disorders (NORD) and its member organizations come together to fight the disease and raise awareness about the condition. Some of the member organizations of NORD are the Association of Gastrointestinal Motility Disorders, Inc., the SBS Cure Project, the Oley Foundation, and the Short Bowel Syndrome Foundation, Inc.
Gattex Drugs - a curse or a boon?
The major obstacle for the market of global short bowel syndrome is the side effects of consuming the approved and prescribed drugs for this condition, which can result in numerous health complications. The extensively used drugs such as Gattex or Revestive can cause cold, nausea, flu, abdominal pain, and headache. Blockage of the bowel, abnormal cell growth resulting in cancer, polyps in the colon, and inflammation or blockage of the gallbladder or pancreas are other related complications arising from these medicines. This conundrum has experts in the industry wonder whether drugs such as Gattex are actually beneficial or harmful for patients.
Unavailability of approved drugs and high mortality rate associated with SBS, especially in developing economies, are few other factors limiting the growth of the market.